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Abstract
Background
There is growing evidence that supports the benefits of early use of caffeine in preterm neo-
nates with RDS; however, no formal recommendations specifying the exact timing of ther-
apy initiation have been provided.
Objectives
We compared neonatal outcomes in infants receiving early (initial dose on the 1st day of life)
and late (initial dose on day 2+ of life) caffeine therapy.
Methods
Using data from a prospective, cohort study, we identified 986 infants32 weeks’ gestation
with RDS and assessed the timing of caffeine therapy initiation, need for ventilatory support,
mortality and incidence of typical complications of prematurity. To adjust for baseline sever-
ity, the early and late caffeine groups were propensity score (PS) matched to 286 infants
(1:1). Clinical outcomes were compared between the PS-matched groups.
Results
Early treatment with caffeine citrate was associated with a significantly reduced need for
invasive ventilation (71.3% vs 83.2%; P = 0.0165) and total duration of mechanical ventila-
tion (mean 5 ± 11.1 days vs 10.8 ± 14.6 days; P = 0.0000) and significantly lower odds of
intraventricular hemorrhage (IVH) (OR 0.4827; 95% CI 0.2999–0.7787) and patent ductus
arteriosus (PDA) (OR 0.5686; 95% CI 0.3395–0.9523). The incidence of bronchopulmonary
dysplasia (BPD) (36.4% vs 45.8%) and rates of moderate and severe BPD were not
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Conclusion
Early caffeine initiation was associated with a decreased need for invasive ventilatory sup-
port and lower incidence of IVH and PDA.
Introduction
Caffeine citrate is a medication commonly used in neonatology and considered the gold stan-
dard in the prevention and treatment of apnea of prematurity. This medication is usually used
during the first days or sometimes even hours of life up to 34–35 weeks of postconceptional
age. No detailed recommendations exist regarding the optimal timing for caffeine therapy
initiation.
A meta-analysis published in 2015 reviewed data from 5 publications on early caffeine
administration [1]. Whilst all the reviewed studies reported the benefits of earlier vs later initi-
ation of caffeine treatment, they differed in their definitions of “early” treatment [1,2,3,4,5].
Most often “early” treatment was defined as treatment initiated within the first 3 days of life.
However, in clinical practice, the threshold for “early” caffeine treatment is constantly shift-
ing towards earlier initiation. Despite the lack of formal recommendations, in neonatal depart-
ments in Poland, caffeine treatment is usually initiated on the first day of life. There are also
supporters of initiating caffeine therapy directly after birth while still in the delivery room.
The wide variety of practices in this regard justifies the need for an analysis evaluating
whether initiation of treatment during the first 24 hours after birth is more beneficial than ini-
tiating during the following days of life. Early therapy is likely to have a positive impact on
reducing the incidence of bronchopulmonary dysplasia (BPD) and persistent ductus arteriosus
(PDA), shortening the duration of mechanical ventilation and lowering the proportion of chil-
dren requiring home oxygen therapy [2,5].
Objective
The objective of our study was to compare the effects of early vs late caffeine citrate adminis-
tration on clinical outcomes in premature infants 32 weeks of gestational age with respira-
tory distress syndrome (RDS).
Methods
This analysis was based on the data collected in a large, multicenter, prospective study, the
NeoPro study, aimed at evaluating adherence to the European Guidelines on the Management
of RDS in neonatal departments in Poland. Here, we report the results of an assessment of the
timing of caffeine citrate treatment and its impact on clinical outcomes.
Data were collected between November 2014 and December 2015 in 42 level-III and 5
level-II neonatal intensive care units using dedicated questionnaires.
Inclusion criteria were as follows: (1) gestational age 32 weeks, (2) diagnosis of RDS
regardless of the severity of radiological findings on chest X-ray, and (3) need for surfactant
treatment. The presence of clinically significant congenital defects was an exclusion criterion.
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The NeoPro study was a non-interventional, observational study. Hence, a particular therapeu-
tic strategy was not decided in advance by the study protocol, but reflected standard care in the
given center and all the medicinal products were prescribed in the usual manner. Consequently,
timing of initiation of caffeine treatment was not protocol-defined but depended upon the routine
practice at study sites. On admission to the NICU a written consent with regard to the use of ther-
apeutic procedures and medicinal products was signed by parents or legal guardians. Clinical data
was collected anonymously, without any identifying information about the individual patients.
The study protocol was approved by the Bioethics Committee of the Medical University of War-
saw (decision AKBE 106/14), in accordance with the principal investigator’s affiliation.
The “early” caffeine treatment group included infants in whom caffeine citrate therapy was
initiated during the first 24 hours after birth, and the “late” treatment group included infants
in whom therapy was started on the second day of life or after.
Study endpoints included the duration of respiratory support and the incidence of BPD
and PDA. As secondary endpoints, we analyzed mortality before hospital discharge and the
rates of intraventricular hemorrhage (IVH) and periventricular leukomalacia (PVL).
BPD was diagnosed at the postconceptional age of 36 weeks or at hospital discharge
depending on which occurred earlier. Diagnostic criteria included the need for supplemental
oxygen for at least 28 days and oxygen dependency at the time of diagnosis (breathing ambient
air, mild BPD;<30% oxygen, moderate BPD; and>30% oxygen: severe BPD) [6]. Intra- and
periventricular hemorrhages were diagnosed using trans-fontanel ultrasonography performed
according to the approved standards and classified using the Papile grading system [7]. The
diagnosis of PDA was made based on echocardiography results and treated with ibuprofen
when hemodynamically significant. Failure to respond to pharmacological therapy was an
indication for surgical ligation [8].
Given that the study was not randomized, we used propensity score matching (PSM) to
adjust for the impact of baseline characteristic differences between the “early” and “late” caf-
feine groups on the final treatment outcomes. The PSM method mimics the randomization
process by matching participants in different groups based on baseline covariates. This statisti-
cal technique allows for the selection of a control group that is as similar as possible to the
study group, with the only difference being "early" or "late" administration of caffeine. The two
groups were matched with respect to the following variables: age, gestational age, birth weight,
place of birth (inborn/outborn), mode of delivery, 5-minute APGAR score, use of antenatal
steroids and need for intubation in the delivery room. For PSM we employed the nearest
neighbor without replacement method [9]. To minimize the number of poor matches, a caliper
equal to 0.05 of the standard deviation of the propensity score was used.
For comparisons between independent variables, the two-sided Student’s t-test (in case of
normal distribution) or U-Mann-Whitney test (non-normal distribution) was used. To com-
pare neonatal outcomes (incidence of typical complications of prematurity), we used Yate’s
continuity corrected chi-square test or Fisher’s exact test. Confidence intervals (95%) for the
odds ratios were calculated using Wald’s method. The level of significance for all comparisons
was established at 5%.
The analysis was performed with R statistical software (version 3.2), Foundation for Statisti-
cal Computing, Vienna, Austria. R MatchIt package (version 2.4) was used for propensity
score analysis.
Results
Of the 986 infants who met inclusion criteria, 888 (90%) received treatment with caffeine cit-
rate. A complete dataset was obtained for 844 newborns. The group included 54.1% males, and
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most infants were inborn (89,3%). The median gestational age was 28 weeks (IQR, 27–30
days), and the median body weight was 1095 g (IQR, 840–1370 g). Extremely low body weight
(ELBW) infants (< 1000 g) constituted 41,6% of the group.
Of the 844 infants, 676 (80,1%) received caffeine treatment during the first 24 hours of life
(“early” caffeine) and 168 (19,9%) received caffeine treatment on the second day of life of later
(“late” caffeine); [Fig 1].
In the latter group, the median (IQR) time to treatment initiation was 4 days (2–10 days).
The two groups differed significantly in antenatal steroid exposure (82.3% vs 71.5% in the
“early” and “late” group, respectively; P = 0.0026) and gestational age, which was lower in the
“early” caffeine group (median 28.1 vs 29.0 weeks; P = 0.0680).
After employing the PSM procedure, two equally numbered groups of 143 infants were
formed that had similar baseline characteristics and no significant differences in any of the
matched variables (Table 1). Clinical outcomes were compared between the propensity
matched cohorts.
Respiratory support
In PS-matched infants, “early” caffeine receipt was associated with a decreased need for inva-
sive ventilation (71.3% vs 83.2%; P = 0.0165) and significantly shorter total duration of
Fig 1. Patient flow diagram. DOL = Day of Life.
https://doi.org/10.1371/journal.pone.0189152.g001
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mechanical ventilation relative to “late” caffeine (mean 5 ±11.1 days vs 10.8 ±14.6 days;
P = 0.0000). A similar difference was not observed in the duration of non-invasive respiratory
support, which did not differ significantly between groups (mean 15.9 ±15.3 days vs 13.7 ±15.2
days; P = 0.1595).
BPD
Although seeming to show a trend, the incidence of BPD (36.4% vs 45.8%) and rates of moder-
ate BPD (5,9% vs 12.1%) and severe BPD (3.4% vs 4.7%) were not statistically significant
between the ‘early’ and the ‘late’ treatment groups [Table 2].
“Early” caffeine was associated with a significantly lower incidence of PDA (25% vs 37%;
P = 0.0427) and significantly reduced odds of PDA (OR 0.5686; 95% CI 0.3395–0.9523) relative
to “late” caffeine. Nevertheless, no statistically significant differences were observed in the
rates of pharmacotherapy for or surgical ligation of PDA (Fig 2).
Secondary endpoints
IVHs were observed more often (60.1%) in the late therapy group than in the early therapy
group (42.1%; P = 0.0039). Early treatment initiation was associated with a significantly
Table 1. Clinical characteristics of the study cohort (N = 844) overall and within groups paired using the PSM method (N = 286).
Characteristics All infants Propensity-matched infants
Early caffeine Late caffeine P value Early caffeine Late caffeine P value
N = 676 N = 168 N = 143 N = 143
GA, weeks
Mean ±SD 28.2 ±2.2 28.5 ±2.4 0.0680 28.6 ±2.1 28.5 ±2.4 0.9618
Median (IQR) 28 (27–30) 29 (27–30) 29 (27–30) 29 (27–30)
Birth weight, g
Mean ±SD 1118 ±357 1155 ±404 0.4397 1174 ±357 1168 ±406 0.8190
Median (IQR) 1090 (840–1345) 1100 (845–1455) 1130 (895–1450) 1100 (850–1485)
Sex
Male, n (%) 364 (54.3) 88 (53.0) 0.8277 77 (53.8) 76 (53.8) 1.0000
Place of birth
Inborn, n(%) 576 (88.9) 147 (90.7) 0.5899 129 (90.2) 133 (93.0) 0.5223
Outborn, n(%) 72 (11.1) 15 (9.3) 14 (9.8) 10 (7.0)
Mode of delivery
C-section, n(%) 533 (79.6) 134 (80.7) 0.8194 111 (77.6) 115 (80.4) 0.6631
Vaginal birth, n(%) 137 (20.4) 32 (19.3) 32 (22.4) 28 (19.6)
Apgar at 5 min.
Mean ±SD 6.5 ±1.9 6.5 ±2.3 0.6388 6.6 ±2.1 6.5 ±6.5 0.9543
Median (IQR) 7 (6–8) 7 (6–8) 7 (6–8) 7 (6–8)
Antenatal steroid use
N (%)# 550 (82.3) 118 (71.5) 0.0026 106 (74.1) 106 (74.1) 1.0000
Intubation in the DR
N (%) 349 (52.2) 91 (54.2) 0.7058 76 (53.1) 77 (53.8) 1.0000
Caffeine therapy, days
Mean ±SD 37.8 ±23.3 24.8 ±19.3 0.0000 35.1 ±25 24.3 ±19.7 0.0000
Median (IQR) 35 (20–52) 21.5 (9.8–36) 31 (19–48) 21 (9–35)
# data on antenatal steroids were unavailable for 11 neonates, including 8 infants in early caffeine and 3 infants in late caffeine groups.
https://doi.org/10.1371/journal.pone.0189152.t001
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reduced risk of IVHs (OR 0.4827; 95% CI 0.2999–0.7787) but had no impact on the occurrence
of the most severe forms of the disease (grade 3 and 4) when compared with late initiation.
PVL was diagnosed in 2.9% infants in the “early” caffeine group and 8% infants in the “late”
caffeine group (P = 0.0610) (Table 2). The rates of mortality before hospital discharge were
almost identical between groups (8.6% vs 8.5%; P = ns)
Discussion
Main finding
This paper is the first large study to investigate the effect of very early caffeine administration
on the outcomes of infants less than 32 weeks gestation. We have shown that administering
caffeine in the first 24 hours of life significantly decreased the need for, and duration of, inva-
sive ventilation compared to matched infants starting caffeine treatment on day two or later.
Table 2. Study endpoints in PS-matched infants.
Early caffeine Late caffeine P value
N = 143 N = 143
Length of hospital stay, days
Mean ±SD 58.1 ±38.7 53.8 ±29.7 0.2413
Median (IQR) 54 (40–72) 49 (32–73)
Need for MV
N (%) 102 (71.3) 119 (83.2) 0.0165
Mechanical ventilation, days
Mean ±SD 5 ±11.1 10.8 ±14.6 0.0000
Median (IQR) 1.0 (0.0–4.0) 4.3 (1.0–15.9)
Non-invasive ventilation, days
Mean ±SD 15.9 ±15.3 13.7 ±15.2 0.1595
Median (IQR) 10 (3–25) 7 (2–23)
Death
N (%) 12 (8.6) 12 (8.5) 1.0000
BPD
No BPD, N (%) 75 (63.6) 58 (54.2) 0.3117
Mild BPD, N (%) 32 (27.1) 31 (29.0)
Moderate BPD, N (%) 7 (5.9) 13 (12.1)
Severe BPD, N (%) 4 (3.4) 5 (4.7)
IVH
N (%) 59 (42.1) 83 (60.1) 0.0039
Grade I, N (%) 14 (26.9) 25 (30.9) 0.7036
Grade II, N (%) 26 (50.0) 36 (44.4)
Grade III, N (%) 5 (9.6) 12 (14.8)
Grade IV, N (%) 7 (13.5) 8 (9.9)
PDA
N (%) 35 (25) 51 (37) 0,0427
Pharmacological closure of PDA
N (%) 14 (43.7) 18 (37.5) 0.7444
Surgical ligation of PDA
N (%) 4 (12.5) 8 (16.7) 0.8479
PVL
N (%) 4 (2.9) 11(8) 0.0610
https://doi.org/10.1371/journal.pone.0189152.t002
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“Early” treatment also significantly reduced the incidence of both intraventricular hemorrhage
and persistent ductus arteriosus.
Previous work
Although caffeine citrate has been used in the prevention and treatment of apnea of prematu-
rity for more than 30 years, its beneficial effects on general morbidity and future psychomotor
development have only recently been documented [2,10].
The 2013 European recommendations emphasized the role of the timing of caffeine initia-
tion, suggesting that earlier treatment initiation is associated with more beneficial effects [11].
However, there have been no specific recommendations made regarding timing of initiation
or duration of treatment.
Some benefits of very early caffeine administration were documented in a randomized,
double-blind trial conducted by Katheria et al. in 2015; however, this pilot study only evaluated
a very small group of 21 infants [12]. Eleven of those newborns received caffeine citrate during
the first 2 hours of life, while the remainder started treatment later (at 12 hours). Lower num-
bers of infants who received very early treatment required intubation in the first 12 hours of
life (3 vs 7 infants) or needed treatment for PDA (2 vs 4 infants). The authors found no differ-
ence in the frequency of intraventricular hemorrhage and, surprisingly, in this study infants in
the ‘early’ group required more days of mechanical ventilation. The timeframes used in this
study differ from ours–making the results not directly comparable. However, similar to this
study, we found fewer infants required mechanical ventilation (71.3% vs 83.2%; P = 0.0165) or
developed a PDA; however, we also found that earlier treatment halved the number of days on
invasive ventilation, and lowered rates of IVH.
A publication by the Canadian Neonatal Network in 2015 reported retrospective data on
5101 newborns from 29 sites [13]. The authors compared outcomes for infants receiving caf-
feine either within the first two days of life or after the third day. Despite the longer time-
frames, in agreement with our results, they found reduced numbers of PDAs (OR, 0.74; 95%
CI 0.62 to 0.89) in the early treatment group. This large study also reported a significant reduc-
tion in BPD (OR 0.81; 95% CI 0.67 to 0.98).
Similar findings were reported in 2014 by both Dobson et al. [14] and a group from Phila-
delphia under the leadership of Taha [15]. Both groups looked at caffeine administration at
0–2 days versus day 3 or later. Both groups found infants receiving caffeine at day three or
later were significantly more likely to develop BPD then those receiving it earlier (Dobson
et al. OR, 0.68; 95% CI, 0.63–0.73; Taha OR 0.69; 95% CI 0.58 to 0.82; P<0.001). Although our
study showed a trend towards reduced BPD, this was not significant.
Few studies have looked at the effect of timing of caffeine administration on IVH. In their
small randomized study, Katheria et al. [12] were unable to demonstrate a significant differ-
ence. Consistent with our results, Taha et al. reported a lower incidence of severe IVH in early
relative to late treatment groups [15]. Disappointingly, in our study we found that although
IVH was decreased overall (OR 0.48; 95% CI 0.29 to 0.78), hemorrhages of the greatest severity
(grade III or IV) occurred with comparable frequency (23.1% vs 24.7%) in both groups. We
also observed a trend towards reduced numbers of patients with PVL (2.9% vs 8%; P = 0.0610)
in the ‘early’ versus the ‘late’ treatment group. This finding is in broad agreement with the
results of the meta-analysis by Park et al. [1] which found a reduction in PVL in infants treated
with caffeine within the first two days of life (P<0.001; OR 0,560; CI 0.494 to 0.635). We would
expect that, similar to the findings of Schmidt et al. [16,17], this will translate into a reduced
incidence of cerebral palsy, although the length of our study means we cannot answer this
question.
Early vs late caffeine in RDS
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Possible mechanism of action
Caffeine is known to stimulate regular breathing, and increase sensitivity to carbon dioxide
[18]. This is likely to improve the success of non-invasive ventilation and lead to the observed
decreased need for, and reduced duration of, invasive ventilation. This, along with the anti-
inflammatory properties of caffeine [19] may contribute to the improved respiratory outcomes
in infants receiving treatment.
The mechanisms behind the ‘non-respiratory’ effects of caffeine treatment continue to be
debated. Lower rates of intraventricular hemorrhage may result from improvements in cere-
bral blood flow, in turn due to fewer periods of intermittent hypoxia which are observed with
caffeine treatment [20].
Although observed in several trials, the decreased incidence of PDA is more difficult to
explain. Mechanisms including improved hemodynamics [21] and the prostaglandin antago-
nistic properties of caffeine [22] are possibilities. Further research is needed to clearly under-
stand the relationship of PDA to caffeine administration.
Limitations of this study
Although prospectively enrolled, this was an observational study, not a randomized trial.
Treatment therefore reflects local practice, and outcomes may have been influenced by con-
founding factors. Given the study involved infants treated at multiple locations, this is of
Fig 2. Comparison of the effects of “early” and “late” caffeine therapy on the risk of typical complications of prematurity.
https://doi.org/10.1371/journal.pone.0189152.g002
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course a significant concern, in particular treatment may have differed between level 2 and
level three centers. We believe our findings remain valid for two reasons. Firstly, the use of
propensity scores imitates randomization as closely as possible, meaning baseline characteris-
tics of infants are similar. Secondly, the large size of the cohort minimizes the impact of con-
founding influences from multiple treatment centers.
This study is also limited by duration; by focusing on the early effects of caffeine treatment
we are unable to comment on any longer-term effects.
Strengths of this study
This study represents a significant group of infants, and is the largest report on the outcomes
of caffeine treatment given within the first day of life. Prospective enrollment and propensity
matching strengthen the certainty of our findings.
Implications for practice
This study adds to the previous body of work showing the benefits of early administration of
caffeine to preterm infants. In agreement with previous work we have shown that early caffeine
reduces the incidence of persistent ductus arteriosus and intraventricular hemorrhage, as well
as reducing the need for invasive ventilation.
Importantly, this paper has narrowed down the timeframe for ‘early’ administration, dem-
onstrating additional benefits for treatment started during the first 24 hours of life.
In light of these results, we recommend starting caffeine treatment in the first 24 hours for
infants less than 32 weeks gestation who required surfactant treatment.
Conclusions
1. Initiating caffeine citrate therapy within the first 24 hours of life in newborns aged32 ges-
tational weeks who required surfactant treatment was associated with an average duration
of mechanical ventilation that was 5 days less than that observed in infants with later ther-
apy initiation.
2. Early treatment with caffeine citrate was associated with a statistically significant reduction
in the total rates of PDA and IVHs; however, lesser reductions were observed in the higher
grades of IVH.
3. On the basis of our findings, we recommend that caffeine treatment for suitable infants
should be started within the first 24 hours of life.
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